conclusions Ang II suppression of pressure-induced constrictor responses in renal interlobar arteries may be mediated, at least in part, by inhibition of β and γENaC protein expression.
Epithelial Na + channels (ENaCs) are heteromultimeric channels formed by α, β, and γENaC proteins. In the kidney, ENaC channels are found in the distal nephron where they regulate blood pressure by contributing to Na + and water reabsorption. Expression of ENaC proteins is tightly regulated by several hormonal factors including steroid and peptide hormones that are critical to blood pressure regulation such as aldosterone and angiotensin II (Ang II). 1, 2 β and γENaC proteins are also expressed in vascular smooth muscle cell (VSMC) of renal vessels where they contribute to pressure-induced constriction in renal interlobar arteries. Pressure-induced constriction, also referred to as myogenic constriction, is initiated by pressure-induced vessel wall stretch. The molecular identity of molecule(s) transducing mechanical stretch into the cell-signaling event remains unknown; however, mechanosensory complexes including β and γENaC proteins are one possibility. [3] [4] [5] [6] Myogenic constriction is a physiologically significant response because it contributes to blood flow autoregulation and may prevent transmission of systemic blood pressure to delicate microvessels. 7, 8 Although hormonal regulation of ENaC proteins has been addressed in epithelial cells, regulation of vascular ENaC remains unknown. We considered the possibility that Ang II may be an important regulator of vascular ENaC because Ang II is a potent regulator of vascular tone and regulates ENaC expression in epithelial tissue. In renal tubules, Ang II has contrasting effects on ENaC expression: stimulates αENaC but inhibits β and γENaC expression. 9 Although renal epithelial ENaC expression is regulated by Ang II, whether Ang II regulates vascular ENaC expression has never been determined. Therefore, the goal of the current study was to determine whether Ang II regulates vascular ENaC expression and function. To test this hypothesis, Sprague-Dawley rats received Ang II via osmotic minipump for 1 week. Renal interlobar arteries were isolated from these animals to assess VSMC ENaC protein expression and myogenic constrictor responses. Our findings suggest Ang II inhibits β and γENaC in renal VSMCs. Furthermore, Ang II inhibits myogenic constriction in renal interlobar arteries.
Methods
Experimental groups. Male Sprague-Dawley rats (275-375 g body weight; Harlan Industries, Indianapolis, IN) were divided into two groups for each experiment; control (saline, 0.5 µl/h)
Background
The importance of β and γ epithelial Na + channel (ENaC) proteins in vascular smooth muscle cell (VSMC)-mediated pressure-induced constriction in renal interlobar arteries has been demonstrated recently. In renal epithelial tissue, ENaC expression is regulated by angiotensin II (Ang II). However, whether Ang II regulates vascular ENaC expression has never been determined. Therefore, the goal of the current investigation was to determine whether Ang II affects vascular ENaC expression and its contribution to pressure-induced constriction.
Methods
To address this goal, Sprague-Dawley rats were infused with Ang II (50 ng/kg/min) via osmotic minipump for 1 week. Mean arterial pressure (MAP) was measured using radiotelemetry. Interlobar arteries were isolated from these animals to assess VSMC ENaC protein expression, pressure-induced constriction, and agonist-induced vascular reactivity. results MAP was not different in control (113 ± 2 mm Hg) and Ang II-(114 ± 2 mm Hg) infused mice. We found that Ang II infusion decreased renal VSMC β and γENaC immunolabeling by 18%. Consistent with this finding, we also found that ENaC-dependent peak pressure-induced constriction was inhibited from 38 ± 3% to 25 ± 1% at 125 mm Hg. Vasoreactivity to KCl, phenylephrine (PE), and acetylcholine (ACh) was unchanged.
articles Angiotensin II and Vascular ENaC and Ang II (50 ng/ml/kg). All animals were maintained on a high salt diet (8% NaCl) at least 1 week prior to Ang II infusion to inhibit endogenous Ang II formation. Animals were housed one per cage in a temperature-controlled room (23 °C) with a 12:12 h light/dark cycle. All protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center.
Telemetric measure of arterial pressure in conscious rats. In a subgroup of rats, arterial pressure was chronically monitored in conscious rats by use of radiotelemetry as previously described. 10 Pressures were sampled at 500 Hz for 20 s every 20 min and averaged in 60-min blocks for analysis with arterial pressure averaged during 24-h periods for daily values.
Ang II infusion. Ang II was infused (50 ng/kg/min) intravenously for 1 week via an osmotic minipump (model 2002; Alza Scientific, Palo Alto, CA) implanted abdominally under isoflurane anesthesia. Following this period, renal vessels were harvested for vessel function and expression studies.
Quantification of ENaC expression in freshly dispersed VSMCs.
To determine the effect of Ang II on ENaC expression, we used quantitative immunolabeling as previously described. For these studies, renal vessels are isolated, and VSMCs enzymatically dispersed and fixed as described previously. 11 Samples were labeled with antibodies to α, β, or γENaC and mouse antismooth muscle α-actin as previously described. 11, 12 All samples were examined using quantitative fluorescence confocal microscopy (TCS-SP2; Leica Microsystems, Exton, PA). All samples were collected, labeled, and imaged side-by-side under identical conditions. Background signal from samples where the primary antibody was omitted was subtracted from all samples. We have used this approach to quantify ENaC expression in VSMCs previously. [11] [12] [13] Data were averaged from three animals in each group.
Cannulation of interlobular arteries for dimensional analysis.
Animals were anesthetized with isoflurane, then both kidneys were excised and placed in ice-cold physiological saline solution (PSS) as previously described. 11, 12 Renal interlobar arteries (121.5 ± 3.3 µm passive (Ca 2+ -free) inner diameter at 75 mm Hg) were studied in a vessel chamber (CH/1/ SH; Living Systems, Burlington, VT) and analyzed using MetaMorph software (Universal Imaging, Downingtown, PA) as described previously. 11, 12 Following an initial incubation period (30 min at 75 mm Hg), a pressure-diameter curve was generated to determine the effect of ENaC inhibition on myogenic constriction as previously described. 12 Arteries were equilibrated for 30 min with benzamil (1 µmol/l, ENaC inhibitor) extraluminally before repeating the pressure-diameter curve. The pressure-diameter curve was repeated in the presence of Ca 2+ -free PSS (same as above PSS plus 2 mmol/l EGTA and omit 1.8 mmol/l CaCl 2 ) to determine the passive pressure-diameter curve. Myogenic constriction was calculated as the percent difference between the active (PSS) and passive (Ca 2+ -free PSS) inner diameter at each pressure.
Effect of Ang II infusion on phenylephrine-, KCl-, and acetylcholine-induced vasoreactivity.
To determine the effect of Ang II on agonist-induced vascular reactivity, we assessed vasoconstriction to the depolarizing stimulus KCl (80 mmol/l) and the α 1 -adrenergic receptor agonist, phenylephrine (PE; 10 −9 -10 −5 mol/l). We also evaluated endothelium-dependent vasodilation with acetylcholine (ACh; 10 −9 -10 −5 mol/l) following preconstriction with 10 −6 mol/l PE. Data are presented as percent vasoconstriction and vasodilation from control.
Statistics. All data are expressed as mean ± s.e. A t-test or twoway analysis of variance with repeated measures was used to make comparisons where appropriate (StatView; SAS Institute, San Francisco, CA). Differences among groups were compared using the Student-Newman-Keuls test. Statistical significance was considered at P < 0.05. 
slow-pressor response to ang ii
The average 24-h mean arterial pressure (MAP) during the 12-day recording period in vehicle and Ang II-infused animals are shown in Figure 1 . In control animals (n = 5), MAP was 115 ± 2 and 113 ± 2 mm Hg during the 6-day control and infusion periods. In Ang II-infused animals (n = 9), MAP increased significantly from 109 ± 2 mm Hg during the control period to 114 ± 2 mm Hg (P = 0.009) during Ang II infusion. MAP was not significantly different between vehicle and Ang II-infused groups (P = 0.77).
effect of ang ii on renal VsMc enac expression
Representative images of α, β, and γENaC and α-smooth muscle actin immunolocalization in renal VSMCs isolated from vehicle and Ang II-treated animals are shown in Figure 2a -c. Quantitation of α, β, and γENaC labeling, normalized to α-smooth muscle actin are shown in Figure 2d . In renal VSMC isolated from vehicle-treated animals, αENaC fluorescence was undetectable above background. Although Ang II infusion significantly increased the expression of αENaC (Figure 2a , P < 0.001), αENaC expression was still only weakly detected. In contrast, β and γENaC were robustly expressed in isolated VSMCs near the membrane from Renal interlobar arteries from vehicle-infused rats maintained internal diameter with increases in intraluminal pressure. In contrast, renal interlobar arteries from Ang II-treated animals dilated with increases in intraluminal pressure. The effect of Ang II infusion on the development of myogenic tone is shown in Figure 3c . Renal interlobar arteries from vehicle-treated rats developed significantly more myogenic tone at 100, 125, and 150 mm Hg (32 ± 3, 38 ± 3, and 34 ± 2%), whereas Ang II infusion reduced myogenic tone (27 ± 2, 25 ± 1, and 24 ± 1 at 100, 125, and 150 mm Hg, respectively). Nearly all myogenic tones were inhibited by ENaC blockade with benzamil (Figure 3c) . The amount of myogenic tone developed following benzamil treatment was not different between vehicle-and Ang II-treated arteries.
ang ii on renal interlobar artery agonist-induced vascular reactivity
Interlobar artery vascular reactivity in vehicle and Ang II-treated animals are shown in Figure 4 . Normalized vasoconstrictor responses to 80 mmol/l KCl and PE (10 −9 -10 −5 mol/l) were not different between groups (Figure 4a,b) . Furthermore, vasodilation to ACh (10 −9 -10 −5 mol/l) was not different in vehicle vs. Ang II-infused animals (Figure 4c ).
discussion
Recently, our laboratory demonstrated the importance of ENaC proteins in renal myogenic vasoconstriction. 11, 12 We have shown that β and γ are expressed in renal artery VSMCs. ENaC proteins are closely related to a family of proteins in the nematode, Caenorhabditis elegans, that form the pore of a mechanosensory ion channel complex in muscle and neurons. 14 articles Angiotensin II and Vascular ENaC mammalian mechanosensors. Empirical evidence supports such a link; ENaC protein and activity are required for mechanosensitive events such as arterial baroreception, touch sensation, and myogenic constriction. 3, 4 Although regulation of tubular ENaC by cardiovascular relevant hormones has been addressed, regulation of vascular ENaCs has never been determined. Therefore, the goal of this study was to determine the importance of one of these many ENaC regulators, Ang II, on vascular ENaC expression and function. The major findings from this study are (i) Ang II decreases β and γENaC and leads to weak expression of αENaC and (ii) significantly inhibits ENaC-dependent myogenic responsiveness in renal interlobar arteries. Our results suggest Ang II differentially regulates ENaC proteins in VSMCs. It is common for ENaC subunits to be differentially regulated. For example, in the distal nephron, aldosterone increases αENaC transcription but not β and γENaC. 1,2 Ang II blockade, in rats fed a low salt diet, inhibits αENaC and stimulates β and γENaC. 9 Similarly, AT1a knockout mice have reduced αENaC and elevated β and γENaC. 15 Consistent with these findings, our current study demonstrates Ang II increases renal VSMC αENaC but decreases β and γENaC. The mechanism(s) of differential expression is unclear but may involve effects on transcription, translation, and degradation. 1, 2 Several lines of evidence suggest that β and γENaC are components of a vascular mechanosensor in the kidney. 11, 12 First, β and γ, but not αENaC, are detected in vascular tissues isolated from rat and mouse renal vessels. 11, 12 Second, pharmacologic inhibition of ENaC channels with amiloride (5 µmol/l) or benzamil (1 µmol/l) abolishes pressureinduced but does not alter agonist-induced constriction. 11, 12 Third, gene-specific silencing, using siRNA or expression of dominant-negative isoforms, specifically abolishes pressureinduced constriction. 11, 12 Consistent with the hypothesis that β and γENaC proteins may mediate pressure-induced constriction, we found that Ang II inhibited the myogenic tone (~25%) to a similar degree as β and γENaC (~18%) expression in the current study. Furthermore, myogenic tone in control and Ang II-infused groups was abolished to the same level (5-8% tone) by ENaC inhibition with 1 µmol/l benzamil, suggesting myogenic tone in renal interlobar arteries, regardless of Ang II, is predominantly dependent on ENaC signaling. Similar to our previous investigations, we were unable to detect αENaC in control renal VSMCs. In contrast, αENaC became detectable by immunofluorescence following chronic Ang II infusion. However, it should be noted that relative to β and γENaC, αENaC expression is extremely low and barely detectable above background. This finding suggests renal VSMC expression of αENaC may be suppressed under normal conditions and upregulated under certain conditions. Our finding that Ang II infusion inhibits pressure-induced constrictor responses in interlobar arteries is consistent with previous investigations. Animal models of Ang II-dependent hypertension (two-kidney, one-clip model, Ang II infusion) have suppressed pressure-induced regulation of afferent arteriolar tone and renal blood flow. [16] [17] [18] [19] [20] [21] In contrast to our current investigation, these studies used higher doses of Ang II and elicited substantial increases in pressure, which are associated with renal injury. In a subsequent study, Inscho et al. demonstrated that the prevention of increases in arterial pressure with Ang II receptor antagonists or triple therapy (hydralazine, hydrochlorothiazide, and reserpine) prevented the autoregulatory dysfunction suggesting that increased blood pressure, rather than Ang II, caused the loss of autoregulatory response. 21 In the current study, MAP increased to 5 mm Hg after 1 week of Ang II. However, MAP in Ang II-infused animals was not different from control animals. We speculate that the low rate of infusion (0.5 µl/h) of the miniosmotic pump likely lead to Ang II degradation and thus circulating levels of Ang II were not sufficient to produce hypertension. Thus, it is unknown whether the small change in pressure or increase in Ang II or both can lead to altered myogenic responsiveness. Additional studies are articles Angiotensin II and Vascular ENaC required to determine the importance of pressure, Ang II, and their interaction on ENaC expression and ENaC-dependent myogenic tone. Our finding that chronic infusion of Ang II suppresses expression of vascular β and γENaC and renal myogenic constriction has implications for hypertension-induced renal injury. The myogenic response has been suggested to be an important mechanism protecting microvessels from injury caused by high systemic pressures, especially in hypertension. 7, 8 As Ang II is elevated in many forms of hypertension, our findings raise the possibility that Ang II suppression of vascular ENaC expression and myogenic constrictor responses may contribute to increased susceptibility to renal injury in hypertension. In summary, our data suggest chronic Ang II infusion suppresses expression of vascular ENaC proteins that contribute to myogenic constriction in renal interlobar arteries.
